Stockscreener 앱 받기
4.05
2.05%
-0.09
전일 마감가:
$4.14
열려 있는:
$4.14
하루 거래량:
189.72K
Relative Volume:
0.30
시가총액:
$408.44M
수익:
-
순이익/손실:
$-26.25M
주가수익비율:
-9.8805
EPS:
-0.4099
순현금흐름:
$-20.05M
1주 성능:
+10.19%
1개월 성능:
+19.62%
6개월 성능:
+36.07%
1년 성능:
-4.59%
1일 변동 폭
$3.98
$4.20
1주일 범위
$3.58
$4.45
52주 변동 폭
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
명칭
Galectin Therapeutics Inc
전화
678-620-3186
주소
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.05 | 360.03M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
541.17 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
791.10 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,026.77 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.06 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.34 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 재개 | H.C. Wainwright | Buy |
| 2020-08-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-13 | 개시 | B. Riley FBR | Buy |
| 2017-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-19 | 개시 | ROTH Capital | Buy |
| 2017-03-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | 다운그레이드 | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-09-21 | 개시 | H.C. Wainwright | Buy |
| 2014-08-01 | 다운그레이드 | Aegis Capital | Buy → Hold |
| 2014-07-30 | 재확인 | MLV & Co | Buy |
| 2014-07-29 | 재확인 | MLV & Co | Buy |
| 2014-04-02 | 재확인 | MLV & Co | Buy |
| 2014-02-10 | 재확인 | Aegis Capital | Buy |
| 2014-01-09 | 재확인 | Aegis Capital | Buy |
| 2013-12-03 | 개시 | MLV & Co | Buy |
| 2013-08-19 | 재확인 | Aegis Capital | Buy |
모두보기
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn
Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn
HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade
Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart
Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus
Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView
Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com
Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative
Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo
GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat
Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewir - The National Law Review
Galectin Therapeutics (GALT) Jumps 7% to $3.45: Biotech Breakout Gains MomentumSentiment Shift - vinanet.vn
Galectin Therapeutics (GALT) Advances 2.48% to $3.3, Holds Above Key Support LevelHigh Reward Trades - dars.gov.et
Galectin Therapeutics (GALT) Holds Steady at $3.10 as Shares Trade Within Tight RangeDebt Free Companies - dars.gov.et
Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion - The Globe and Mail
Galectin chairman converts $105.8 million debt to equity By Investing.com - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Galectin chairman converts $105.8 million debt to equity - Investing.com
Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet - 富途牛牛
Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Galectin Therapeutics (GALT) Slides 8% as Small-Cap Biotech Selling Pressure IntensifiesDemand Zone - dars.gov.et
Galectin Therapeutics (GALT) Drops 8% as Shares Approach Key Support at $2.82High Low Breadth - dars.gov.et
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Galectin Therapeutics Inc (GALT) Cash Flow - tradingkey.com
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.470|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.390|Chg%:-0.080 - TradingKey
Galectin Therapeutics (NASDAQ:GALT) Breaks a Key Trend Line - Kalkine Media
GALT stock reacts to Galectin Therapeutics Q1 2026 cash position and R&D progress - Ad-hoc-news.de
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat
GALT stock gains support as Galectin Therapeutics keeps cash focus - Ad-hoc-news.de
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics Inc (GALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Galectin Therapeutics Inc 주식 (GALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Option Exercise |
3.04 |
16,250 |
49,400 |
16,250 |
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Sale |
5.13 |
16,250 |
83,284 |
0 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Option Exercise |
1.23 |
22,268 |
27,390 |
28,768 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Option Exercise |
1.23 |
7,732 |
9,510 |
14,232 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Sale |
5.04 |
22,268 |
112,231 |
6,500 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Sale |
5.00 |
7,732 |
38,660 |
6,500 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Option Exercise |
2.50 |
47,467 |
118,668 |
47,467 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Option Exercise |
2.37 |
4,570 |
10,814 |
2,533 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Sale |
5.04 |
47,467 |
239,234 |
0 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Sale |
5.00 |
4,570 |
22,850 |
0 |
7.79%
자본화:
|
볼륨(24시간):